Facebook
Twitter
Telegram
Report an ErrorInozyme Pharma Balance Sheet 2011-2024 | INZY
Annual Balance Sheet Inozyme Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
11.1 M | -28 M | -19.9 M | -28 M | -31.6 M | -36 M | - | - | - | - | - | - | - |
Long Term Debt |
44.8 M | 4.14 M | 2.64 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
910 K | 816 K | 731 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 1.29 M | 77.9 M | 55 M | - | - | - | - | - | - | - |
Total Current Liabilities |
14.7 M | 14.7 M | 11.6 M | 9.97 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
60.4 M | 20.8 M | 14.3 M | 11.3 M | 81.2 M | 57.4 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-286 M | -215 M | -148 M | -91.1 M | -34.7 M | -14.9 M | - | - | - | - | - | - | - |
Total Assets |
201 M | 139 M | 124 M | 169 M | 47.9 M | 43.5 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
34.6 M | 32.9 M | 23.3 M | 28 M | - | - | - | - | - | - | - | - | - |
Book Value |
140 M | 118 M | 109 M | 158 M | -33.2 M | -13.9 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
140 M | 118 M | 109 M | 158 M | -33.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Inozyme Pharma
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
45 M | 44.8 M | 32.1 M | 31.9 M | 24.2 M | 4.14 M | 4.07 M | 2.24 M | 2.44 M | 2.64 M | 2.83 M | 3.01 M | 3.19 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
58.1 M | 60.4 M | 45.5 M | 45.3 M | 38.4 M | 20.8 M | 19.2 M | 12.8 M | 14.7 M | 14.3 M | 11.8 M | 9.98 M | 10 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 3.24 M | 3.24 M | 3.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-309 M | -286 M | -264 M | -248 M | -232 M | -215 M | -196 M | -180 M | -165 M | -148 M | -129 M | -115 M | -102 M | -91.1 M | -91.1 M | -91.1 M | -91.1 M | -34.7 M | -34.7 M | -34.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
177 M | 201 M | 206 M | 151 M | 142 M | 139 M | 154 M | 162 M | 109 M | 124 M | 138 M | 148 M | 159 M | 169 M | 169 M | 169 M | 169 M | 47.9 M | 47.9 M | 47.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
20.6 M | 34.6 M | 46.9 M | 40.8 M | 49 M | 32.9 M | 44 M | 62.6 M | 31.9 M | 23.3 M | 27.2 M | 26.2 M | 16.5 M | 28 M | 28 M | 28 M | 28 M | 31.6 M | 31.6 M | 31.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
119 M | 140 M | 160 M | 106 M | 103 M | 118 M | 135 M | 149 M | 94.2 M | 109 M | 126 M | 138 M | 149 M | 158 M | 158 M | 158 M | 158 M | 44.7 M | 44.7 M | 44.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
119 M | 140 M | 160 M | 106 M | 103 M | 118 M | 135 M | 149 M | 94.2 M | 109 M | 126 M | 138 M | 149 M | 158 M | 158 M | 158 M | 158 M | -33.2 M | -33.2 M | -33.2 M | -18.8 M | -13.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency